Market Overview:
The Pruritus Therapeutic market estimated at USD 12.64 Billion in the year 2022, is projected to reach a revised size of USD 17.84 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2023-2030.
Itchy skin is an uncomfortable, annoying sensation that causes individuals to scratch. Dry skin is a common cause of itchy skin, also known as pruritus. It's more frequent in older people since their skin dries out with age. The skin may appear normal, red, rough, or bumpy depending on the reason for the itching. Scratching repeatedly can result in raised, thickened skin that might bleed or become infected. Many people find relief from self-care methods such as frequent moisturizing, gentle cleansers, and lukewarm baths. Long-term relief requires determining and treating the source of itchy skin. Pruritus can also be caused by medical conditions such as kidney failure, liver disease, thyroid disease, cancer, and diabetes. Antibiotics, antifungals, anticonvulsants, and a few natural remedies such as topical application of coconut oil, vitamin E, and honey are utilized to treat pruritus.
Top Key Players in Pruritus Therapeutic Market:
AbbVie Inc., Sanofi SA, Galderma Laboratories LP, EPI Health LLC, Cara Therapeutics, Actavis, Trevi Therapeutics, Novartis AG, Pfizer Inc., Merck & Co. Inc., Sun Pharmaceuticalc, GlaxoSmithKlinePLC, Glenmark Pharmaceuticals Ltd., and Other Major Players.
Market Dynamics and Factors for the Pruritus Therapeutic Market:
Drivers:
An increasing number of individuals suffering from dermatitis and allergic diseases
Dermatitis is a general term for conditions that cause inflammation of the skin. It includes atopic dermatitis (eczema), contact dermatitis, and seborrheic dermatitis (dandruff). These conditions cause red rashes, dry skin, and itchiness among other symptoms. Atopic dermatitis (AD) is one of the most frequent inflammatory skin diseases in humans, affecting up to 20% of children living in higher-income countries. The first signs of the disease usually develop between the 3rd and 6th months of life, and about 60% of cases occur within the first two years of life; 80% of affected children experience symptoms before the 6th year of life. AD is more common in adults than previously thought, with up to nearly 10% affected. These cases result from persistent or recurrent childhood AD or the new onset of AD later in life.
Opportunities:
Development of innovative solutions for treating the pruritic condition
The increasing prevalence of pruritus among individuals has stimulated market players to develop innovative solutions for the treatment of the disease. This has resulted in partnerships among key players for the development and production of advanced drugs. For instance, in April 2022, Almirall S.A. announced a research collaboration with the University of Dundee to develop a novel approach against chronic and debilitating dermatological diseases characterized by itch, or pruritus. The collaboration will build on Dr. John Foerster's team at the University of Dundee's proprietary immune-based treatment for chronic inflammatory conditions. Furthermore, some of the key players have raised funding to boost the development of novel drugs.
Segmentation Analysis of the Pruritus Therapeutic Market:
By Drug Class, the corticosteroids segment is anticipated to lead the growth of the pruritus therapeutics market over the projected period. Over the last 40 years, topical corticosteroids have been the mainstay of atopic dermatitis treatment. Hydrocortisone was the first corticosteroid to be used; today 30 additional corticosteroid compounds are approved for the treatment of atopic dermatitis.
By Disease Type, the atopic dermatitis segment is expected to have the highest share of the pruritus therapeutics market in the forecasted period. Atopic Dermatitis (AD), also known as eczema, is a common inflammatory skin condition.
Regional Analysis of the Pruritus Therapeutic Market:
The North American region is anticipated to dominate the pruritus therapeutics market over the forecasted period attributed to the growing prevalence of chronic diseases such as diabetes, eczema, and other skin-related disorders. According to the National Eczema Association, 31.6 million Americans (10.1%) have some form of eczema, with prevalence peaking during childhood. It is also estimated that one in every ten people will develop eczema during their lifetime, with prevalence peaking in childhood.
Key Industry Development:
In January 2022, AbbVie announced that RINVOQ® (upadacitinib) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease has not responded in comparison to past treatment and is not adequately regulated with other medications or injections.
